Abby Hardy, Author at BioTuesdays

Developments

Hepion to present on CRV431’s anti-fibrotic activity at the Liver Meeting 2019

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will present preclinical data on CRV431 at The Liver Meeting 2019. Dr. Ure’s presentation will address CRV431’s ability to decrease liver fibrosis in a carbon...

November 7, 2019

Developments

Hepion CRV431 reduces fibrosis in new model of NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) reported preclinical findings where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of liver fibrosis in a Western diet (WD) animal model of NASH. The WD...

November 7, 2019

Markets

Paradigm ups Profound Medical PT to C$45

Paradigm Capital raised its price target for Profound Medical (TSX:PRN; NASDAQ:PROF) to C$45 from C$40 based on the company’s commercialization plan for TULSA-PRO. The stock closed at $12.70 on the TSX on Nov. 5...

November 6, 2019

Developments

Inovio Pharma reports positive interim data from Phase 2 glioblastoma trial

Inovio Pharmaceuticals (NASDAQ:INO) reported positive interim results from its Phase 2 study of INO-5401 for the treatment of newly-diagnosed glioblastoma multiforme (GBM), the most common and aggressive type of brain...

November 5, 2019

Developments

Notch Therapeutics to commercialize industrial-scale T cell therapies

Upstart Notch Therapeutics plans to commercialize industrial-scale allogeneic gene-edited T cell therapies to deliver cost-effective treatments to patients with cancer or immune deficiencies. Incubated at Toronto’s...

November 5, 2019

Feature

Lobo Genetics enabling personalized cannabis product selection based on consumers’ genes

Closely-held Lobo Genetics is taking its cannabis genetic profile testing to the next level. “We started with genetic tests and genetic profiling and now we are complementing that by helping guide consumers to the right...

November 5, 2019

Executive Moves

Orthofix appoints Jon Serbousek as president and CEO

Jon Serbousek Orthofix Medical (NASDAQ:OFIX) appointed Jon Serbousek as president, CEO and a director of its board, effective immediately. Mr. Serbousek succeeds Brad Mason, who previously announced his retirement. Mr...

November 1, 2019

Developments

Biostage submits IND for Cellspan esophageal implant

Biostage (OTCQB:BSTG) filed an IND with the FDA for its Cellspan esophageal implant (CEI). According to Biostage, patients who require surgical treatment for esophageal disease have complication rates of more than 50%...

October 30, 2019

Developments

Surmodics gets FDA breakthrough device designation for sirolimus-coated balloon

Surmodics (NASDAQ:SRDX) received FDA breakthrough device designation for its sirolimus-coated balloon (SCB), called Sundance, for the treatment of critical limb ischemia (CLI) and below-the-knee arterial disease. CLI...

October 29, 2019

Developments

TG Therapeutics umbralisib meets primary endpoint in Phase 2b lymphoma trial

TG Therapeutics (NASDAQ:TGTX) reported the follicular lymphoma (FL) cohort of the its Phase 2b pivotal trial of umbralisib met the primary endpoint of overall response rate (ORR). The trial included 188 FL patients who...

October 29, 2019

Author - Abby Hardy

Hepion to present on CRV431’s anti-fibrotic activity at the Liver Meeting 2019

Hepion CRV431 reduces fibrosis in new model of NASH

Paradigm ups Profound Medical PT to C$45

Inovio Pharma reports positive interim data from Phase 2 glioblastoma trial

Notch Therapeutics to commercialize industrial-scale T cell therapies

Lobo Genetics enabling personalized cannabis product selection based on consumers’ genes

Orthofix appoints Jon Serbousek as president and CEO

Biostage submits IND for Cellspan esophageal implant

Surmodics gets FDA breakthrough device designation for sirolimus-coated balloon

TG Therapeutics umbralisib meets primary endpoint in Phase 2b lymphoma trial

Subscribe